Effects of carbamazepine on plasma haloperidol levels

Michael W. Jann; Larry Ereshefsky; Stephen R. Saklad; Donald R. Seidel; Chester M. Davis; Neil R. Burch; Charles L. Bowden

doi:10.1097/00004714-198504000-00010

Effects of carbamazepine on plasma haloperidol levels

Michael W. Jann, Larry Ereshefsky, Stephen R. Saklad, Donald R. Seidel, Chester M. Davis, Neil R. Burch, Charles L. Bowden

Research output: Contribution to journal › Article › peer-review

94 Scopus citations

Abstract

Plasma haloperidol levels were monitored in three schizophrenic patients when carbamazepine was either added or discontinued. The percent decrease in plasma haloperidol levels due to concomitant carbamazepine therapy was between 59% and 61%. The effects of carbamazepine on plasma haloperidol levels were noted to occur in 2 to 3 weeks. Although no adverse effects occurred in the patients during therapy, careful monitoring of clinical symptoms and plasma haloperidol levels is recommended.

Original language	English
Pages (from-to)	106-109
Number of pages	4
Journal	Journal of Clinical Psychopharmacology
Volume	5
Issue number	2
DOIs	https://doi.org/10.1097/00004714-198504000-00010
State	Published - Apr 1985

Access to Document

10.1097/00004714-198504000-00010

Cite this

@article{ffa64272cfe049bd9196b24b66ee5ac6,

title = "Effects of carbamazepine on plasma haloperidol levels",

abstract = "Plasma haloperidol levels were monitored in three schizophrenic patients when carbamazepine was either added or discontinued. The percent decrease in plasma haloperidol levels due to concomitant carbamazepine therapy was between 59% and 61%. The effects of carbamazepine on plasma haloperidol levels were noted to occur in 2 to 3 weeks. Although no adverse effects occurred in the patients during therapy, careful monitoring of clinical symptoms and plasma haloperidol levels is recommended.",

author = "Jann, {Michael W.} and Larry Ereshefsky and Saklad, {Stephen R.} and Seidel, {Donald R.} and Davis, {Chester M.} and Burch, {Neil R.} and Bowden, {Charles L.}",

year = "1985",

month = apr,

doi = "10.1097/00004714-198504000-00010",

language = "English",

volume = "5",

pages = "106--109",

journal = "Journal of Clinical Psychopharmacology",

issn = "0271-0749",

publisher = "Lippincott Williams and Wilkins Ltd.",

number = "2",

}

TY - JOUR

T1 - Effects of carbamazepine on plasma haloperidol levels

AU - Jann, Michael W.

AU - Ereshefsky, Larry

AU - Saklad, Stephen R.

AU - Seidel, Donald R.

AU - Davis, Chester M.

AU - Burch, Neil R.

AU - Bowden, Charles L.

PY - 1985/4

Y1 - 1985/4

N2 - Plasma haloperidol levels were monitored in three schizophrenic patients when carbamazepine was either added or discontinued. The percent decrease in plasma haloperidol levels due to concomitant carbamazepine therapy was between 59% and 61%. The effects of carbamazepine on plasma haloperidol levels were noted to occur in 2 to 3 weeks. Although no adverse effects occurred in the patients during therapy, careful monitoring of clinical symptoms and plasma haloperidol levels is recommended.

AB - Plasma haloperidol levels were monitored in three schizophrenic patients when carbamazepine was either added or discontinued. The percent decrease in plasma haloperidol levels due to concomitant carbamazepine therapy was between 59% and 61%. The effects of carbamazepine on plasma haloperidol levels were noted to occur in 2 to 3 weeks. Although no adverse effects occurred in the patients during therapy, careful monitoring of clinical symptoms and plasma haloperidol levels is recommended.

UR - http://www.scopus.com/inward/record.url?scp=0021950571&partnerID=8YFLogxK

U2 - 10.1097/00004714-198504000-00010

DO - 10.1097/00004714-198504000-00010

M3 - Article

C2 - 3988968

AN - SCOPUS:0021950571

SN - 0271-0749

VL - 5

SP - 106

EP - 109

JO - Journal of Clinical Psychopharmacology

JF - Journal of Clinical Psychopharmacology

IS - 2

ER -

Effects of carbamazepine on plasma haloperidol levels

Abstract

Access to Document

Other files and links

Fingerprint

Cite this